Impact Factor: 1.264

Open Access Published since November 7, 2014

Translational Neuroscience

ISSN: 2081-6936

Editor-in-chief: Olivier David

Submit manuscript

About this journal

Why subscribe and read

Premier source of high quality research; Reports novel findings that are likely to change the direction of thinking and practice in biomedical sciences; Covers research findings in all subfields of neuroscience (behavioral, cognitive, computational, developmental and regeneration, molecular, neural aging, neuroanatomy, neurobiology, neurochemistry, neuroendocrinology, neurogenetics, neuroimmunology, neuropathology, neuropharmacology, neurophysiology, methodology, neurotoxicology and systems neuroscience) as well as in the fields of neurology, neurosurgery and psychiatry; Represents international forum for the dissemination of research data aiming at the exchange of ideas thus facilitating the collaboration between researchers from different countries.

Why submit

Unbiased, fast and comprehensive peer review; Web-based manuscript submission system; Free English language correction of grammar and style for authors.

Your Benefits

Translational Neuroscience provides a closer interaction between basic and clinical neuroscientists to expand understanding of brain structure, function and disease, and translate this knowledge into clinical applications and novel therapies of nervous system disorders.

Special Issue Proposals

Translational Neuroscience welcomes all proposals for topical and special issues. Publishing SI gives you a chance to examine the specific topics, exchange knowledge on the latest trends in neuroscience and highlight the most valuable findings. SI may be a great idea to summarize the conference, scientific meeting, or symposium.　

The SI is managed by the Guest Editors (supported by the editorial office), who should be recognized experts in the discipline. They are responsible for promoting the issue, pre-screening the manuscripts, handling the peer-review process (with strict cooperation with Managing Editor), and making decisions about the Special Issue submissions.

The articles published in SI will be a part of our regular volume (with all benefits). Also, depending on the number of submitted articles, we can provide discounts for the picked, distinguished papers.　

If you have a remarkable idea for an SI (or any questions), please fill out the following form, and contact the Managing Editor (jedrzej.daszkiewicz@degruyter.com).

Abstracting and Indexing

Translational Neuroscience is covered by the following services:

Baidu Scholar
Cabells Journalytics
Case
Chemical Abstracts Service (CAS) - CAplus
Chemical Abstracts Service (CAS) - SciFinder
Chronos Hub
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO (relevant databases)
EBSCO Discovery Service
EMBASE
Genamics JournalSeek
GoOA
Google Scholar
Indextra (Medical Library)
Japan Science and Technology Agency (JST)
J-Gate
Journal Citation Reports/Science Edition
JournalTOCs
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Norwegian Register for Scientific Journals, Series and Publishers
ProQuest (relevant databases)
Publons
PubMed
PubMed Central
PubsHub
QOAM (Quality Open Access Market)
ReadCube
Reaxys
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
Web of Science - Biological Abstracts
Web of Science - BIOSIS Previews
Web of Science - Science Citation Index Expanded
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

Topics

External Links

Volume 14 Issue 1

January 2023

Research Articles

Open Access February 9, 2023

HIF-1α participates in secondary brain injury through regulating neuroinflammation

Xiaojian Xu, Mengshi Yang, Bin Zhang, Jinqian Dong, Yuan Zhuang, Qianqian Ge, Fei Niu, Baiyun Liu

Article number: 20220272

More Download PDF

Abstract

A deeper understanding of the underlying biological mechanisms of secondary brain injury induced by traumatic brain injury (TBI) will greatly advance the development of effective treatments for patients with TBI. Hypoxia-inducible factor-1 alpha (HIF-1α) is a central regulator of cellular response to hypoxia. In addition, growing evidence shows that HIF-1α plays the important role in TBI-induced changes in biological processes; however, detailed functional mechanisms are not completely known. The aim of the present work was to further explore HIF-1α-mediated events after TBI. To this end, next-generation sequencing, coupled with cellular and molecular analysis, was adopted to interrogate vulnerable events in a rat controlled cortical impact model of TBI. The results demonstrated that TBI induced accumulation of HIF-1α at the peri-injury site at 24 h post-injury, which was associated with neuronal loss. Moreover, gene set enrichment analysis unveiled that neuroinflammation, especially an innate inflammatory response, was significantly evoked by TBI, which could be attenuated by the inhibition of HIF-1α. Furthermore, the inhibition of HIF-1α could mitigate the activation of microglia and astrocytes. Taken together, all these data implied that HIF-1α might contribute to secondary brain injury through regulating neuroinflammation.

Open Access March 6, 2023

Omega-3 polyunsaturated fatty acids alleviate early brain injury after traumatic brain injury by inhibiting neuroinflammation and necroptosis

Yali Wu, Jing Zhang, Xiaoyan Feng, Wei Jiao

Article number: 20220277

More Download PDF

Abstract

Presently, traumatic brain injury (TBI) is a leading contributor to disability and mortality that places a considerable financial burden on countries all over the world. Docosahexaenoic acid and eicosapentaenoic acid are two kinds of omega-3 polyunsaturated fatty acids (ω-3 PUFA), both of which have been shown to have beneficial biologically active anti-inflammatory and antioxidant effects. However, the neuroprotective effect of ω-3 PUFA in TBI has not been proven, and its probable mechanism remains obscure. We suppose that ω-3 PUFA can alleviate early brain injury (EBI) via regulating necroptosis and neuroinflammation after TBI. This research intended to examine the neuroprotective effect of ω-3 and its possible molecular pathways in a C57BL/6 mice model of EBI caused by TBI. Cognitive function was assessed by measuring the neuronal necroptosis, neuroinflammatory cytokine levels, brain water content, and neurological score. The findings demonstrate that administration of ω-3 remarkably elevated neurological scores, alleviated cerebral edema, and reduced inflammatory cytokine levels of NF-κB, interleukin-1β (IL-1β), IL-6, and TNF-α, illustrating that ω-3 PUFA attenuated neuroinflammation, necroptosis, and neuronal cell death following TBI. The PPARγ/NF-κB signaling pathway is partially responsible for the neuroprotective activity of ω-3. Collectively, our findings illustrate that ω-3 can alleviate EBI after TBI against neuroinflammation and necroptosis.

Open Access March 18, 2023

The correlation between non-arteritic anterior ischemic optic neuropathy and cerebral infarction

Xiaochun Li, Xiaolu Cao, Fenglou Ma, Peipei Jia, Fuyin Wang, Xiaoguang Cao

Article number: 20220281

More Download PDF

Abstract

Background The aim of this study was to explore the correlation between non-arteritic anterior ischemic optic neuropathy (NAION) and cerebral infarction (CI). Moreover, the ocular and systemic parameters are also compared between NAION patients with or without CI. Methods Retrospective analysis is performed for NAION patients and the controls. The controls were collected at the eye outpatient with cranial computed tomography (CT), and data of blood triglyceride, cholesterol, low-density lipoprotein, high-density lipoprotein, and apolipoprotein B were drawn. The diagnosed NAION patients with cranial CT are included, and data of clinical history and routine clinical examination were drawn from the medical record. Visual acuity, intraocular pressure (IOP), visual field, and visual evoked potential were also drawn. Results Eighty-two unilateral and 6 bilateral patients, totally 94 eyes for 88 NAION patients and 69 controls are included. NAION and control patients have matched age, gender, and weight. There is no difference in triglyceride, cholesterol, low-density lipoprotein, high-density lipoprotein, and apolipoprotein B between these two groups. NAION patients (43.18%, 38/88) have a higher ratio of CI than the controls (14.49%, 10/69) ( p = 0.000). For NAION, the odds ratio (OR) of CI is 2.691 ( p = 0.011). Body mass index, height, and IOP show no significant difference between NAION patients with or without CI. NAION patients with CI have a significant higher ratio of hypertension than those without CI, and the OR of HBP is 2.623 ( p = 0.008). Conclusions The correlation between NAION and CI is possible as NAION patients have a significant higher ratio with CI. In NAION patients, hypertension is a risk factor for those with CI.

Open Access March 21, 2023

Enriched environment can reverse chronic sleep deprivation-induced damage to cellular plasticity in the dentate gyrus of the hippocampus

Xue Shixing, Hou Xueyan, Ren Yuan, Tang Wei, Wang Wei

Article number: 20220280

More Download PDF

Abstract

Objective We studied whether enriched environment (EE), a classic epigenetics paradigm, can prevent cellular plasticity damage caused by chronic sleep deprivation (SD). Methods We performed SD in mice by a modified multi-platform method (MMPM). Mice in the SD group were deprived of sleep for 18 h a day. In addition, half of the mice in the chronic SD group were exposed to EE stimuli for 6 h per day. Immunostaining analyzed neurogenesis and neural progenitor cell-differentiated phenotypes in the hippocampal dentate gyrus (DG) region. Result At 13 weeks, compared with the control group, SD severely impaired the proliferation and differentiation of neural stem cells, and EE completely reversed the process. SD can induce gliosis in the mouse hippocampus, and EE can delay the process. Conclusion: Our results suggest that chronic SD may damage the neurogenesis in the DG of the hippocampus. However, enrichment stimulation can reverse the processing by promoting neuronal repair related to neuronal plasticity.

Commentary

Open Access March 14, 2023

Translation of surface electromyography to clinical and motor rehabilitation applications: The need for new clinical figures

Roberto Merletti, Federico Temporiti, Roberto Gatti, Sanjeev Gupta, Giorgio Sandrini, Mariano Serrao

Article number: 20220279

More Download PDF

Abstract

Advanced sensors/electrodes and signal processing techniques provide powerful tools to analyze surface electromyographic signals (sEMG) and their features, to decompose sEMG into the constituent motor unit action potential trains, and to identify synergies, neural muscle drive, and EEG–sEMG coherence. However, despite thousands of articles, dozens of textbooks, tutorials, consensus papers, and European and International efforts, the translation of this knowledge into clinical activities and assessment procedures has been very slow, likely because of lack of clinical studies and competent operators in the field. Understanding and using sEMG-based hardware and software tools requires a level of knowledge of signal processing and interpretation concepts that is multidisciplinary and is not provided by most academic curricula in physiotherapy, movement sciences, neurophysiology, rehabilitation, sport, and occupational medicine. The chasm existing between the available knowledge and its clinical applications in this field is discussed as well as the need for new clinical figures. The need for updating the training of physiotherapists, neurophysiology technicians, and clinical technologists is discussed as well as the required competences of trainers and trainees. Indications and examples are suggested and provide a basis for addressing the problem. Two teaching examples are provided in the Supplementary Material.

Retraction

Open Access February 14, 2023

Retraction of “Eriodictyol corrects functional recovery and myelin loss in SCI rats”

Chenggang Li, Chunfang Wang

Article number: 20220275

Download PDF

Volume 5 (2014)

Volume 4 (2013)

Volume 3 (2012)

Volume 2 (2011)

Volume 1 (2010)

5-year Impact Factor	2.086
Cite Score	2.1
Impact Factor	1.264
Journal Citation Indicator	0.31
SCImago Journal Rank	0.349
Source Normalized Impact per Paper	0.557

Submit

MANUSCRIPTS
Translational Neuroscience encourages the submission of both substantial full-length bodies of work and shorter manuscripts that report novel findings. There are no specific length restrictions for the overall manuscript or individual sections; however, we urge the authors to present and discuss their findings in a concise and accessible manner.

All submissions must be made via online submission system Editorial Manager. In case of problems, please contact the Managing Editor of this journal (jedrzej.daszkiewicz@degruyter.com).

For detailed information, please see Instruction for Authors.

EDITORIAL POLICY
Unpublished material: Submission of a manuscript implies that the work described is not copyrighted, published or submitted elsewhere, except in abstract form. The corresponding author should ensure that all authors approve the manuscript before its submission.
Ethical conduct of research: The authors must describe and confirm safeguards to meet ethical standards when applicable. See Editorial Policy for details.
Conflict of interest: When authors submit a manuscript, they are responsible for recognizing and disclosing financial and/or other conflicts of interest that might bias their work and/or could inappropriately influence his/her judgment. If no specified acknowledgement is given, the Editors assume that no conflict of interest exists. Authors are encouraged to fill in the ICMJE Conflicts of Interest Form (available here) and send it in the electronic format to the Managing Editor.
Copyright: All authors retain copyright, unless – due to their local circumstances – their work is not copyrighted. The copyrights are governed by the Creative-Commons Attribution Only license (CC-BY) which is compliant with Plan-S. We may also publish a paper under CC-BY-NC-ND license on author's request. The corresponding author grants the journal the license to use of the article, by signing the License To Publish. Scanned copy of license should be sent to the journal, as soon as possible.
Authorship: Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be named in an Acknowledgement section. The corresponding author should ensure that all appropriate co-authors (according to the above definition) and no inappropriate co-authors are included in the author list of the manuscript, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.
Peer Review process: Our standard policy requires each paper to be reviewed by at least two Referees and the peer-review process is single-blind. The Editors reserve the right to decline the submitted manuscript without review, if the studies reported are not sufficiently novel or important to merit publication in the journal. Manuscripts deemed unsuitable (insufficient originality or of limited interest to the target audience) are returned to the author(s) without review. The Editor seeks advice from experts in the appropriate field. Research articles and communications are refereed by a minimum of two reviewers, review papers by at least three. Authors are requested to suggest persons competent to review their manuscript. However, please note that this will be treated only as a suggestion, and the final selection of reviewers is exclusively the Editor's decision. The final decision of acceptance in made by Managing Editor or, in case of conflict, by the Editor-in-Chief.
Scientific Misconduct: This journal publishes only original manuscripts that are not also published or going to be published elsewhere. Multiple submissions/publications, or redundant publications (re-packaging in different words of data already published by the same authors) will be rejected. If they are detected only after publication, the journal reserves the right to publish a Retraction Note. In each particular case Editors will follow COPE’s Core Practices and implement the advices.

Editorial

Editor-in-Chief
Olivier David, Grenoble Institute of Neuroscience, France

Managing Editor
Jędrzej Daszkiewicz, De Gruyter

Editorial Advisory Board
Sabine Bahn, University of Cambridge, UK
Helen Barbas, Boston University, USA
Gavin J. Clowry, Newcastle University, UK
Sylvain Doré, University of Florida – College of Medicine, USA
Michael Duff Davis, University of Texas, USA
Luciano Fadiga, University of Ferrara, Italy
Roman Haberl, University of Munich, Germany
Jürgen Konczak, University of Minnesota, USA
Ivica Kostoviæ, Zagreb University, Croatia
Cynthia A. Lemere, Harvard University, USA
Jürgen K. Mai, Heinrich Heine University, Germany
Glenn E. Morris, Keele University, UK
Vladimir Parpura, University of Alabama, Birmingham, USA
Giulio M. Pasinetti, Mount Sinai School of Medicine, USA
Marina Picciotto, Yale University, USA
Lucia Machova Urdzikova, Institute of Experimental medicine, Prague, Czech Republic
Menno Witter, Kavli Institute for Systems Neuroscience / Centre for Neural Computation, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
Midori Yenari, University of California, USA

Editorial Board
Joseph Antony, Sunnybrook Research Institute, Canada
Derek J. Blake, Cardiff University, UK
Dara Cannon, National University of Ireland Galway
Marco Catani, King's College London, UK
Laurence Coutellier, Stanford University, USA
Beatrice D’Orsi, Royal College of Surgeons in Ireland, Ireland
Ari Christian Dienel, University of Texas, USA
Bogdan Draganski, Lausanne University Hospital CHUV, Switzerland
Raffaele Falsaperla, Policlinico Universitario di Catania, Italy
Heidi Fuller, University Hospital of North Staffordshire, UK
Stephen D. Ginsberg, New York University, USA
Deepali M. Gupta, The University of Texas Southwestern Medical Center, United States
Thomas Heinbockel, Howard University College of Medicine, USA
Hans-Ulrich Klein, Columbia University, United States.
Blaž Koritnik, University Medical Centre Ljubljana, Slovenia
Asit Kumar, School of Medicine, University of Maryland, USA
Xiaoli Li, Beijing Normal University, China
Lu Lu, The University of Tennessee Health Science Center, USA
Fernando Maestú, Complutense University of Madrid, Spain
Damien D. Pearse, University of Miami, USA
Ronald E. See, Westmont College, USA
Idan Shalev, Pennsylvania State University, USA
Xiaolei Shi, Guangzhou Medical University, China
Rohan de Silva, University College London, UK
Tara Spires-Jones, Harvard University, USA
Jasminka Štefulj, Ruðer Boškoviæ Institute, Croatia
Yasin Temel, Maastricht University, The Netherlands
Paul Thompson, University of California, USA
Fabrizio Vecchio, IRCCS San Raffaele Pisana, Italy
Massimiliano Valeriani, Ospedale Baby Jesus Paediatric Hospital,Rome, Italy
Jinhuan Wang, Tianjin Neurosurgery Institute, China
Aron Weller, Bar Ilan University, Israel
Thomas M. Wisniewski, New York University, USA
Guo-Rong Wu, University of North Carolina, United States
Kelvin Yen, The University of Southern California, USA

Publisher
DE GRUYTER Poland
Bogumiła Zuga 32A Str.
01-811 Warsaw, Poland
T: +48 22 701 50 15

Editorial Contact
Jędrzej Daszkiewicz, Managing Editor
Jedrzej.Daszkiewicz@degruyter.com

Assistant Managing Editor
Deepan Selvaraj, Compuscript
AssistantManagingEditor@degruyter.com

(Deutsch)

Type: Journal
Language: English
Publisher: De Gruyter Open Access
First published: November 7, 2014
Publication Frequency: 1 Issue per Year
Audience: Researchers interested in the topic of neuroscience.